

REMARKS/ARGUMENTS

The Restriction action dated 18 July 2006 required election between claim groups I-III. Applicants herein elect claim group I, including claims 1-11.

Claims 6-9 and 12-20 are cancelled without prejudice or disclaimer. Applicants elect the IL-1 trap in response to the species election requirement, described throughout the specification including at paragraph [0024]. Claim 1 is amended to recite the specific IL-1 antagonist described in the specification at paragraph [0024]. Claim 11 is amended to recite subcutaneous or intravenous routes of administration. No new matter is added by this amendment.

Conclusion

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 18 July 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

It is believed that no fee is due with the submission of this response. In the event it is determined that a fee is due, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650 for the amount of that fee.

Respectfully submitted


Valeta Gregg, Ph.D., Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 593-1077 (direct)